Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Fundamental Analysis

NASDAQ:XENE - Nasdaq - CA98420N1050 - Common Stock - Currency: USD

39.16  -0.57 (-1.43%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XENE. XENE was compared to 571 industry peers in the Biotechnology industry. While XENE has a great health rating, there are worries on its profitability. XENE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XENE had negative earnings in the past year.
XENE had a negative operating cash flow in the past year.
In the past 5 years XENE always reported negative net income.
XENE had a negative operating cash flow in each of the past 5 years.
XENE Yearly Net Income VS EBIT VS OCF VS FCFXENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

XENE has a better Return On Assets (-22.52%) than 74.87% of its industry peers.
Looking at the Return On Equity, with a value of -23.58%, XENE belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
Industry RankSector Rank
ROA -22.52%
ROE -23.58%
ROIC N/A
ROA(3y)-16.32%
ROA(5y)-18.17%
ROE(3y)-17%
ROE(5y)-22.17%
ROIC(3y)N/A
ROIC(5y)N/A
XENE Yearly ROA, ROE, ROICXENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XENE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENE Yearly Profit, Operating, Gross MarginsXENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

XENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XENE has more shares outstanding
XENE has more shares outstanding than it did 5 years ago.
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XENE Yearly Shares OutstandingXENE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
XENE Yearly Total Debt VS Total AssetsXENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 44.31 indicates that XENE is not in any danger for bankruptcy at the moment.
The Altman-Z score of XENE (44.31) is better than 97.86% of its industry peers.
XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 44.31
ROIC/WACCN/A
WACC8.38%
XENE Yearly LT Debt VS Equity VS FCFXENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

XENE has a Current Ratio of 23.27. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
XENE's Current ratio of 23.27 is amongst the best of the industry. XENE outperforms 95.72% of its industry peers.
XENE has a Quick Ratio of 23.27. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
XENE has a better Quick ratio (23.27) than 95.72% of its industry peers.
Industry RankSector Rank
Current Ratio 23.27
Quick Ratio 23.27
XENE Yearly Current Assets VS Current LiabilitesXENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for XENE have decreased by -6.42% in the last year.
The Revenue for XENE has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-6.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.96%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.47% on average over the next years. This is quite good.
XENE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 199.28% yearly.
EPS Next Y-16.36%
EPS Next 2Y-18.2%
EPS Next 3Y-15.72%
EPS Next 5Y12.47%
Revenue Next Year-85.78%
Revenue Next 2Y55.47%
Revenue Next 3Y172.6%
Revenue Next 5Y199.28%

3.3 Evolution

XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XENE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENE Price Earnings VS Forward Price EarningsXENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XENE Per share dataXENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as XENE's earnings are expected to decrease with -15.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.2%
EPS Next 3Y-15.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XENE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENON PHARMACEUTICALS INC

NASDAQ:XENE (2/24/2025, 10:28:37 AM)

39.16

-0.57 (-1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners101.8%
Inst Owner Change-94.58%
Ins Owners0.12%
Ins Owner Change0%
Market Cap2.99B
Analysts88.18
Price Target58.85 (50.28%)
Short Float %4.73%
Short Ratio8.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.69%
Min EPS beat(2)-5.1%
Max EPS beat(2)8.49%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-5.1%
Max EPS beat(4)17.35%
EPS beat(8)5
Avg EPS beat(8)3%
EPS beat(12)7
Avg EPS beat(12)0.73%
EPS beat(16)9
Avg EPS beat(16)-2.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.66%
PT rev (3m)1.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.47%
EPS NY rev (3m)-0.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.88%
Revenue NY rev (3m)-5.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.54
P/tB 3.54
EV/EBITDA N/A
EPS(TTM)-2.82
EYN/A
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0
BVpS11.07
TBVpS11.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.52%
ROE -23.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.32%
ROA(5y)-18.17%
ROE(3y)-17%
ROE(5y)-22.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.27
Quick Ratio 23.27
Altman-Z 44.31
F-Score4
WACC8.38%
ROIC/WACCN/A
Cap/Depr(3y)187.43%
Cap/Depr(5y)252.63%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.96%
EPS Next Y-16.36%
EPS Next 2Y-18.2%
EPS Next 3Y-15.72%
EPS Next 5Y12.47%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-85.78%
Revenue Next 2Y55.47%
Revenue Next 3Y172.6%
Revenue Next 5Y199.28%
EBIT growth 1Y-27.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.02%
EBIT Next 3Y-12.02%
EBIT Next 5YN/A
FCF growth 1Y-115.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.24%
OCF growth 3YN/A
OCF growth 5YN/A